1
|
Taylor SN, Eckert K, Rucki AA, VanSickler M, Price JA, Gutierrez E, Lizzi M, Cammarata CL, Von Bredow B, Wolfe DM, Harris JM, Gregory SM, Greene WH, Vaughan LM. Evaluation of the Onclarity HPV assay on the high-throughput COR system. Expert Rev Mol Diagn 2021; 21:333-342. [PMID: 33849372 DOI: 10.1080/14737159.2021.1894132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Background: Here we compare the performance of the high-throughput BD COR System (COR) to the Viper LT System (Viper) using the BD Onclarity HPV assay.Research Design and Methods: Remnant clinical specimens, contrived specimens in SurePath (BD) and PreservCyt (Hologic) media, and prospective clinical specimens in BD Cervical Brush Diluent (CBD) were tested. Outcomes included intra-laboratory agreement of Onclarity results on COR and inter-system agreement between COR and Viper.Results: Onclarity reproducibility on COR resulted in standard deviation and correlation of variation of Ct values ranging from 0.14 to 1.98 and 0.49% to 2.15%, respectively, for contrived specimens, and 0.9-3.08 and 2.89-9.21%, respectively, for clinical specimens. In the COR and Viper clinical agreement study, OPA for Onclarity ranged from 97.1%-98.9%, depending on the collection media type. PPA values for pooled, HPV(+) specimens at low positive (C95), and moderate positive (3XC95) target concentrations were ≥95.0% and 100%, respectively; PPA values associated with HPV 16, 18, 31, 45, 33/58, 52, 35/39/68, 51, and 56/59/66, individually, ranged from 93.8%-100%.Conclusions: Onclarity performance on COR is equivalent to Viper, and is accurate and reproducible for detection of all high-risk HPV genotypes, with a throughput of 330 results from a single 8-hour shift.
Collapse
Affiliation(s)
- Stephanie N Taylor
- Section of Infectious Disease, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Karen Eckert
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Agnieszka A Rucki
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Michael VanSickler
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - James A Price
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Erin Gutierrez
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Mike Lizzi
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Catherine L Cammarata
- Section of Infectious Disease, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Benjamin Von Bredow
- Penn State College of Medicine, M.S. Hershey Medical Center, Hershey, PA, USA
| | - David M Wolfe
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - James M Harris
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Sean M Gregory
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| | - Wallace H Greene
- Penn State College of Medicine, M.S. Hershey Medical Center, Hershey, PA, USA
| | - Laurence M Vaughan
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, USA
| |
Collapse
|
2
|
Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, Ackerman R, Cooper CK. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. J Clin Microbiol 2020; 59:e02338-20. [PMID: 33023911 PMCID: PMC7771450 DOI: 10.1128/jcm.02338-20] [Citation(s) in RCA: 93] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 10/01/2020] [Indexed: 12/23/2022] Open
Abstract
The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specimens from individuals with COVID-19 symptoms. Two studies were completed to determine clinical performance. In the first study, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID-19 symptoms (≤7 days from symptom onset [DSO], ≥18 years of age) were utilized to compare Veritor with the Lyra SARS-CoV-2 PCR assay (Lyra). In the second study, nasal specimens from 361 participants with COVID-19 symptoms (≤5 DSO, ≥18 years of age) were utilized to compare performance of Veritor to that of the Sofia 2 SARS Antigen FIA test (Sofia 2). The positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) were the primary outcomes. In study 1, the PPA for Veritor, compared to Lyra, ranged from 81.8 to 87.5% across the 0 to 1 and 0 to 6 DSO ranges. In study 2, Veritor had PPA, NPA, and OPA values of 97.4, 98.1, and 98.1%, respectively, with Sofia 2. Discordant analysis showed one Lyra positive missed by Veritor and five Lyra positives missed by Sofia 2; one Veritor positive result was negative by Lyra. Veritor met FDA emergency use authorization (EUA) acceptance criteria for SARS-CoV-2 antigen testing for the 0 to 5 and 0 to 6 DSO ranges (PPA values of 83.9% and 82.4%, respectively). Veritor and Sofia 2 showed a high degree of agreement for SARS-CoV-2 detection. The Veritor test allows for more rapid COVID-19 testing utilizing easy-to-collect nasal swabs but demonstrated <100% PPA compared to PCR.
Collapse
Affiliation(s)
- Stephen Young
- Tricore Reference Laboratory, Albuquerque, New Mexico, USA
| | - Stephanie N Taylor
- Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | | | - Katey G Varnado
- Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | - Celine Roger-Dalbert
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USA
| | - Amanda Montano
- Tricore Reference Laboratory, Albuquerque, New Mexico, USA
| | | | | | - Catherine Fernandez
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, San Diego, California, USA
| | - Karen Eckert
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USA
| | - Jeffrey C Andrews
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USA
| | - Huimiao Ren
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, San Diego, California, USA
| | | | - Ronald Ackerman
- Comprehensive Clinical Research, LLC, West Palm Beach, Florida, USA
| | - Charles K Cooper
- Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USA
| |
Collapse
|
3
|
Abstract
BACKGROUND Chlamydia and gonorrhea coinfection outside of healthcare facilities is less well known. GOAL To determine the co-occurrence of both sexually transmitted diseases (STDs) among high school students participating in a school-based screening and to assess the relevance of dual treatment recommendations in this population. STUDY DESIGN During the 1998 to 1999 school year, 5,877 students attending an urban U.S. school district were screened for chlamydia and gonorrhea using urine ligase chain reaction assays. RESULTS Overall, 451 students had chlamydia, 117 had gonorrhea, including 50 who had both STDs. The gonorrhea and chlamydia co-infections were 50/451 (11.1%) and 50/117 (42.7%), respectively. STD symptoms were reported by 16.0% of students having both infections, 7.7% of those having gonorrhea only, and 5.0% of students having chlamydia only (P = 0.01). CONCLUSIONS The rates of coinfection in this population exceeded those that justify dual treatment in patient-care settings. Chlamydia and gonorrhea co-occurrence may be highly prevalent among certain populations not attending patient-care settings.
Collapse
Affiliation(s)
- Malanda Nsuami
- Department of Medicine, Section of Infectious Diseases, School of Medicine in New Orleans, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
| | | | | | | | | |
Collapse
|